New progress in basic research of uveitis caused by human T lymphocyte leukemia virus type Ⅰ infection

doi:10.3877/cma.j.issn.2095-2007.2017.06.008

Abstract

Abstract:

Human T lymphotropic virus (HTLV) is a retrovirus that currently has 3 subtypes, namely HTLV-Ⅰ and HTLV-Ⅱ and HTLV-Ⅲ, HTLV-Ⅰ and adult T cell leukemia(ATL), HTLV-Ⅰ associated myelopathy(HAM) and uveitis on. HTLV-Ⅰ infection can not only cause uveitis, but also may cause a variety of other ocular symptoms. At present, most scholars believe that HTLV-Ⅰ infection induced uveitis (HAU) is due to the infection of HTLV-Ⅰ T lymphocytes in vivo, leading to cytokine infection gathered in the eye, causing inflammation of the eye. In this paper, the pathogenesis, clinical features, diagnostic methods, treatment methods and the relationship between HAU and other diseases are reviewed.

Key words: Human T lymphocytic leukemia virus type Ⅰ, Uveitis, Fundamental research

Xiaojuan Wang, Dan Zhu, Yong Tao. New progress in basic research of uveitis caused by human T lymphocyte leukemia virus type Ⅰ infection[J]. Chinese Journal of Ophthalmologic Medicine(Electronic Edition), 2017, 07(06): 279-283.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhykyxzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-2007.2017.06.008

https://zhykyxzz.cma-cmc.com.cn/EN/Y2017/V07/I06/279

References 75

[1]	Poiesz B,Maytal J,Horowitz S, et al. Progressive nemaline rod myopathy in a woman coinfected with HIV－1 and HTLV－2[J]. Mount Sinai Journal of Medicine New York, 1993, 60(3): 242-246.
[2]	Carneiroproietti AB,Catalansoares BC,Castrocosta CM, et al. HTLV in the Americas: challenges and perspectives[J]. Revista panamericana de salud publica, 2006, 19(1): 44-53.
[3]	Sagawa K,Mochizuki M,Masuoka K, et al. Immunopathological mechanisms of human T cell lymphotropic virus type 1 (HTLV－Ⅰ) uveitis. Detection of HTLV－Ⅰ－infected T cells in the eye and their constitutive cytokine production[J]. J Clinical Inves, 1995, 95(2): 852-858.
[4]	Kase S,Namba K,Kitaichi N, et al. Clinical features of human T lymphotropic virus type 1－associated uveitis in Hokkaido, Japan[J]. Japanese Journal of Ophthalmology, 2013, 57(4): 379-384.
[5]	Filippone C,Betsem E,Tortevoye P, et al. A Severe Bite From a Nonhuman Primate Is a Major Risk Factor for HTLV－1 Infection in Hunters From Central Africa[J]. Clinical Infectious Diseases, 2015, 60(11): 1667-1676.
[6]	Rathsam－Pinheiro RH,Boa－Sorte N,Castro－Lima－Vargens C, et al. Ocular lesions in HTLV－1 infected patients from Salvador, State of Bahia: the city with the highest prevalence of this infection in Brazil[J]. Revista Da Sociedade Brasileira De Medicina Tropical, 2009, 42(6): 633-637.
[7]	Bangham CR. HTLV－1 infections[J]. Journal of Clinical Pathology, 2000, 53(8): 581-586.
[8]	Koju K,Manabu M. HTLV－1 uveitis[J]. Frontiers in Microbiology, 2012, 3(2): 270-274.
[9]	Gonçalves DU,Proietti FA,Ribas JGR, et al. Epidemiology, treatment, and prevention of human T－cell leukemia virus type 1－associated diseases[J]. Clinical Microbiology Reviews, 2010, 23(3): 577-589.
[10]	Satou Y,Matsuoka M. HTLV－1 and the host immune system: how the virus disrupts immune regulation, leading to HTLV－1 associated diseases[J]. Journal of Clinical & Experimental Hematopathology Jceh, 2010, 50(1): 1-8.
[11]	Olière S,Douville R,Sze A, et al. Modulation of innate immune responses during human T－cell leukemia virus (HTLV－1) pathogenesis[J]. Cytokine & Growth Factor Reviews, 2011, 22(4): 197-210.
[12]	Furuta RA,Sugiura K,Kawakita S, et al. Mouse Model for the Equilibration Interaction between the Host Immune System and Human T－Cell Leukemia Virus Type 1 Gene Expression[J]. Journal of Virology, 2002, 76(6): 2703-2713.
[13]	Jacobson S,Shida H,Mcfarlin DE, et al. Circulating CD8^＋ cytotoxic T lymphocytes specific for HTLV－Ⅰ pX in patients with HTLV－Ⅰ associated neurological disease.[J]. Nature, 1990, 348(6298): 245-248.
[14]	Komatsu N,Wang Y,Malissen B, et al. Heterogeneity of Natural Foxp3^＋ T Cells: A Committed Regulatory T－Cell Lineage and an Uncommitted Minor Population Retaining Plasticity[J]. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106(6): 1903-1908.
[15]	Bangham CR,Osame M. Cellular immune response to HTLV－1[J]. Oncogene, 2005, 24(39): 6035-6046.
[16]	Ono A,Mochizuki M,Yamaguchi K, et al. Increased number of circulating HTLV－1 infected cells in peripheral blood mononuclear cells of HTLV－1 uveitis patients: a quantitative polymerase chain reaction study[J]. Brit J Ophthalmol, 1995, 79(3): 270-276.
[17]	Mita S,Sugimoto M,Nakamura M, et al. Increased human T lymphotropic virus type－1 (HTLV－1) proviral DNA in peripheral blood mononuclear cells and bronchoalveolar lavage cells from Japanese patients with HTLV－1－associated myelopathy[J]. American Journal of Tropical Medicine & Hygiene, 1993, 48(2): 170-177.
[18]	Levin MC,Fox RJ,Lehky T, et al. PCR－in situ hybridization detection of human T－cell lymphotropic virus type 1 (HTLV－1) tax proviral DNA in peripheral blood lymphocytes of patients with HTLV－1－associated neurologic disease[J]. Journal of Virology, 1996, 70(2): 924-933.
[19]	Maruyama M,Shibuya H,Harada H, et al. Evidence for aberrant activation of the interleukin－2 autocrine loop by HTLV－1－encoded p40 x, and T3/Ti complex triggering[J]. Cell, 1987, 48(2): 343-350.
[20]	Yoshida M,Miyoshi I,Hinuma Y. Isolation and characterization of retrovirus from cell lines of human adult T－cell leukemia and its implication in the disease[J]. Proceedings of the National Academy of Sciences of the United States of America, 1982, 79(6): 2031-2035.
[21]	Smith MR,Greene WC. Type Ⅰ human T cell leukemia virus tax protein transforms rat fibroblasts through the cyclic adenosine monophosphate response element binding protein/activating transcription factor pathway[J]. Journal of Clinical Investigation, 1991, 88(3): 1038-1042.
[22]	Rebouissou S,Imbeaud S,Balabaud C, et al. HNF1alpha inactivation promotes lipogenesis in human hepatocellular adenoma independently of SREBP－1 and carbohydrate－response element－binding protein (ChREBP) activation.[J]. Journal of Biological Chemistry, 2007, 282(19): 14437-14446.
[23]	Jaroscak J,Goltry K,Smith A, et al. Augmentation of umbilical cord blood (UCB) transplantation with ex vivo－expanded UCB cells: results of a phase 1 trial using the AastromReplicell System.[J]. Blood, 2003, 101(12): 5061-5067.
[24]	Chan CC,Benezra D,Rodrigues MM, et al. Immunohistochemistry and electron microscopy of choroidal infiltrates and Dalen－Fuchs nodules in sympathetic ophthalmia[J]. Ophthalmology, 1985, 92(4): 580-590.
[25]	Meeker ND,Hickey WF,Korngold R, et al. Multiple loci govern the bone marrow－derived immunoregulatory mechanism controlling dominant resistance to autoimmune orchitis[J]. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92(12): 5684-5688.
[26]	Ono A,Ikeda E,Mochizuki M, et al. Provirus load in patients with human T－cell leukemia virus type 1 uveitis correlates with precedent Graves' disease and disease activities[J]. Jpn J Cancer Res, 1998, 89(6): 608-614.
[27]	Millánrodríguez AC,Fernándezcid C,Garcíacampello M, et al. Intermediate uveitis due to human T－cell lymphotropic virus type 1[J]. Archivos De La Sociedad Española De Oftalmología, 2012, 87(2): 44-46.
[28]	Merle H,Cabre P,Olindo S, et al. Ocular lesions in 200 patients infected by the human T－cell lymphotropic virus type 1 in martinique (French West Indies)[J]. Am J Ophthalmol, 2002, 134(2): 190-195.
[29]	Takahashi T,Takase H,Urano T, et al. Clinical features of human T－lymphotropic virus type 1 uveitis: a long－term follow－up[J]. Ocular Immunology & Inflammation, 2000, 8(4): 235-241.
[30]	Yukawa E,Urano T,Nakahara M, et al. Pattern－reversal visual evoked potentials in patients with human T－lymphotropic virus type 1 uveitis[J]. Current Eye Research, 2006, 31(1): 37-42.
[31]	Yoshimura K,Mochizuki M,Araki S, et al. Clinical and Immunologic Features of Human T－cell Lymphotropic Virus Type Ⅰ Uveitis[J]. Am J Ophthalmol, 1993, 116(2): 156-163.
[32]	Pinheiro SR,Martins－Filho OA,Ribas JG, et al. Immunologic markers, uveitis, and keratoconjunctivitis sicca associated with human T－cell lymphotropic virus type 1[J]. Am J Ophthalmol, 2006, 142(5): 811-815.
[33]	Ohba N,Nakao K,Isashiki Y, et al. Clinical features of HTLV－Ⅰ associated uveitis determined in multicenter collaborative study. Study Group for HTLV－Ⅰ Associated Ocular Diseases.[J]. Japanese Journal of Ophthalmology, 1994, 38(2): 168-174.
[34]	Cohen DB,Glasgow BJ. Bilateral optic nerve cryptococcosis in sudden blindness in patients with acquired immune deficiency syndrome[J]. Ophthalmology, 1993, 100(11): 1689-1694.
[35]	Denning DW,Armstrong RW,Lewis BH, et al. Elevated cerebrospinal fluid pressures in patients with cryptococcal meningitis and acquired immunodeficiency syndrome[J]. American Journal of Medicine, 1991, 91(3): 267-272.
[36]	Maruki C,Nakano H,Shimoji T, et al. Loss of vision due to cryptococcal optochiasmatic arachnoiditis and optocurative surgical exploration－case report[J]. Neurologia medico－chirurgica, 1988, 28(7): 695-697.
[37]	Takeda A,Ishibashi T,Sonoda KH. Epidemiology of Uveitis , Caused by HTLV－1 , Toxoplasmosis , and Tuberculosis ; the Three Leading Causes of Endemic Infectious Uveitis in Japan[J]. Ocul Immunol Inflamm , 2016 , 7(6): 1-5.
[38]	Pinheiro SR,Carneiroproietti AB,Limamartins MV, et al. HTLV－Ⅰ/Ⅱ seroprevalence in 55 Brazilian patients with idiopathic uveitis[J]. Revista Da Sociedade Brasileira De Medicina Tropical, 1996, 29(4): 383-384.
[39]	Sakurai T,Yukawa E,Hara Y, et al. Indocyanine green angiography in patients with human T cell－lymphotropic virus type 1 uveitis[J]. Graefes Arch Clin Exp Ophthalmol , 2002 , 240(2): 101-105.
[40]	Proietti FA,Carneiro－Proietti ABF,Catalan－Soares BC, et al. Global epidemiology of HTLV－Ⅰ infection and associated diseases[J]. Oncogene, 2005, 24(39): 6058-6068.
[41]	Oniki T,Murata T,Sakamoto T, et al. A Case of Human T Lymphotropic Virus Type Ⅰ－associated Uveitis with Cystoid Macular Edema[J]. Folia ophthalmologica Japonica , 1995 , 46(11) : 1196-1199.
[42]	Munk MR,Kiss CG,Steiner I, et al. Systematic correlation of morphologic alterations and retinal function in eyes with uveitis－associated cystoid macular oedema during development, resolution and relapse[J]. British Journal of Ophthalmology, 2013, 97(10): 1289-1296.
[43]	Liu MM,Furusato E,Cao X, et al. Ocular manifestations and pathology of adult T－cell leukemia/lymphoma associated with human T－lymphotropic virus type 1[J]. Rare Tumors, 2010, 2(4): e63.
[44]	Warwar RE,Bullock JD,Ballal D. Cystoid macular edema and anterior uveitis associated with latanoprost use. Experience and incidence in a retrospective review of 94 patients[J]. Ophthalmology, 1998, 105(2): 263-268.
[45]	Alm A,Stjernschantz J. Effects on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. A comparison with timolol. Scandinavian Latanoprost Study Group[J]. Ophthalmology, 1995, 102(12): 1743-1752.
[46]	Ziai N,Dolan JW,Kacere RD, et al. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes[J]. Archives of Ophthalmology, 1993, 111(10): 1351-1358.
[47]	Watson P,Stjernschantz J. A six－month, randomized, double－masked study comparing latanoprost with timolol in open－angle glaucoma and ocular hypertension. The Latanoprost Study Group[J]. Ophthalmology, 1996, 103(1): 126-137.
[48]	Flach AJ,Jampol LM,Weinberg D, et al. Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine[J]. American Journal of Ophthalmology, 1991, 112(5): 514-519.
[49]	Alm A,Villumsen J. PhXA34, a new potent ocular hypotensive drug. A study on dose－response relationship and on aqueous humor dynamics in healthy volunteers[J]. Archives of Ophthalmology, 1991, 109(11): 1564-1568.
[50]	Bito LZ,Stjernschantz J,Resul B, et al. The ocular effects of prostaglandins and the therapeutic potential of a new PGF2 alpha analog, PhXA41 (latanoprost), for glaucoma management[J]. Journal of Lipid Mediators, 1993, 6(3): 535-543.
[51]	Jaffe GJ,Martin D,Callanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty－four－week results of a multicenter randomized clinical study[J]. Ophthalmology, 2006, 113(6): 1020-1028.
[52]	Aung T,Chew PT,Yip CC, et al. A randomized double－masked crossover study comparing latanoprost 0.005% with unoprostone 0.12% in patients with primary open－angle glaucoma and ocular hypertension[J]. Am J Ophthalmol, 2001, 131(5): 636-642.
[53]	Nakao K,Ohba N,Nakagawa M, et al. Clinical course of HTLV－Ⅰ－associated uveitis[J]. Japanese Journal of Ophthalmology, 1999, 43(5): 404-409.
[54]	Kawai H,Mitsui T,Yokoi K, et al. Evidence of HTLV－Ⅰ in thyroid tissue in an HTLV－Ⅰ carrier with Hashimoto's thyroiditis[J]. Journal of Molecular Medicine, 1996, 74(5): 275-278.
[55]	Tamiya S,Matsuoka M,Takemoto S, et al. Adult T cell leukemia following HTLV－Ⅰ－associated myelopathy/tropical spastic paraparesis: case reports and implication to the natural course of ATL[J]. Leukemia, 1995, 9(10): 1768-1770.
[56]	Leons FE,Costa CM,Gaffga N. Discrepancy, coincidence or evidence in chronic idiopathic spastic paraparesis throughout the world. A meta－analysis on 2811 patients[J]. Arquivos de neuro－psiquiatria, 1997, 55(3): 530-535.
[57]	Listed N. Mantakassa: an epidemic of spastic paraparesis associated with chronic cyanide intoxication in a cassava staple area of Mozambique. 2. Nutritional factors and hydrocyanic acid content of cassava products. Ministry of Health, Mozambique[J]. Bulletin of the World Health Organization, 1984, 62(3): 485-492.
[58]	Listed N. Mantakassa: an epidemic of spastic paraparesis associated with chronic cyanide intoxication in a cassava staple area of Mozambique. 1. Epidemiology and clinical and laboratory findings in patients. Ministry of Health, Mozambique[J]. Bulletin of the World Health Organization, 1984, 62(3): 477-484.
[59]	Mead SH,Proukakis C,Wood N, et al. A large family with hereditary spastic paraparesis due to a frame shift mutation of the spastin (SPG4) gene: association with multiple sclerosis in two affected siblings and epilepsy in other affected family members[J]. Journal of Neurology Neurosurgery & Psychiatry, 2001, 71(6): 788-791.
[60]	Hino S,Katamine S,Miyata H, et al. Primary prevention of HTLV－1 in Japan[J]. Leukemia, 1997, 11 (Suppl. 1): 57-59.
[61]	Iwanaga M,Chiyoda S,Kusaba E, et al. Trends in the seroprevalence of HTLV－1 in Japanese blood donors in Nagasaki Prefecture, 2000－2006[J]. International Journal of Hematology, 2009, 90(2): 186-190.
[62]	Stuver SO,Tachibana N,Okayama A, et al. Determinants of HTLV－1 seroprevalence in Miyazaki Prefecture, Japan: a cross－sectional study[J]. Journal of Acquired Immune Deficiency Syndromes, 1992, 5(1): 12-18.
[63]	Watanabe T,Iwasaki Y,Tashiro K, et al. No Evidence of HTLV－1 Infection in Japanese Multiple Sclerosis Patients in Polymerase Chain Reaction[J]. Jpn J Cancer Res, 2010, 80(11): 1017-1020.
[64]	Bandeira LM,Uehara SN,Asato MA, et al. High Prevalence of HTLV－1 Infection among Japanese Immigrants in Non－endemic Area of Brazil[J]. Plos Neglected Tropical Diseases, 2015, 9(4): e0003691.
[65]	Otani M,Honda N,Xia PC, et al. Distribution of Two Subgroups of Human T－Lymphotropic Virus Type 1 (HTLV－1) in Endemic Japan[J]. Tropical Medicine & Health, 2012, 40(2): 55-58.
[66]	Nakamura T. HTLV－Ⅰ－associated myelopathy/tropical spastic paraparesis (HAM/TSP): the role of HTLV－Ⅰ－infected Th1 cells in the pathogenesis, and therapeutic strategy[J]. Folia Neuropathologica, 2009, 47(2): 182-194.
[67]	Nagai M,Utsunomiya T,Takenouchi N, et al. Failure to detect HTLV type 1 DNA from HTLV type 1－seronegative patients with chronic progressive spastic paraparesis in Kagoshima[J]. Aids Research & Human Retroviruses, 2002, 18(14): 1089-1090.
[68]	Poiesz BJ,Ruscetti FW,Gazdar AF, et al. Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T－cell lymphoma[J]. Proceedings of the National Academy of Sciences of the United States of America, 1980, 77(12): 7415-7419.
[69]	Nose H,Saito M,Usuku K, et al. Clinical symptoms and the odds of human T－cell lymphotropic virus type 1－associated myelopathy/ tropical spastic paraparesis (HAM/TSP) in healthy virus carriers: Application of best－fit logistic regression equation based on host genotype, age, and provirus[J]. Journal of Neurovirology, 2006, 12(3): 171-177.
[70]	Link H,Tibbling G. Principles of albumin and IgG analyses in neurological disorders.Ⅲ. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis[J]. Scandinavian Journal of Clinical & Laboratory Investigation, 1977, 37(5): 397-401.
[71]	Schönbach C,Nokihara K,Bangham CR, et al. Identification of HTLV－1－Specific CTL Directed against Synthetic and Naturally Processed Peptides in HLA－B*3501 Transgenic Mice[J]. Virology, 1996, 226(1): 102-112.
[72]	Albietz JM,McLennan SG,Lenton LM. Ocular surface management of photorefractive keratectomy and laser in situ keratomileusis[J]. American Journal of Ophthalmology, 1900, 19(6): 636-644.
[73]	Sauvageot P,Julio G,Alvarez d TJ, et al. Femtosecond laser－assisted laser in situ keratomileusis versus photorefractive keratectomy: Effect on ocular surface condition[J]. Journal of Cataract & Refractive Surgery, 2017, 43(2): 167-173.
[74]	Bower KS,Sia RK,Ryan DS, et al. Chronic dry eye in photorefractive keratectomy and laser in situ keratomileusis: Manifestations, incidence, and predictive factors[J]. J Cataract Refract Surg, 2015, 41(12): 2624-2634.
[75]	Pflugfelder SC,Tseng SC,Yoshino K, et al. Correlation of goblet cell density and mucosal epithelial membrane mucin expression with rose bengal staining in patients with ocular irritation[J]. Ophthalmology, 1997, 104(2): 223-235.

Please choose a citation manager

Content to export